Breaking News Instant updates and real-time market news.

JCP

J.C. Penney

, EFX

Equifax

09:12
11/10/17
11/10
09:12
11/10/17
09:12

On The Fly: Pre-market Movers

UP AFTER EARNINGS: J.C. Penney (JCP), up 17.8%... Equifax (EFX), up 1%... Disney (DIS), up 2.9%... BioLife Solutions (BLFS), up 10.7%... Hertz (HTZ), up 11.2%... NVIDIA (NVDA), up 3.5%... Immunomedics (IMMU), up 10.2%. DOWN AFTER EARNINGS: CAE (CAE), down 1.1%... Trade Desk (TTD), down 12.5%... Redfin (RDFN), down 10.6%.

JCP

J.C. Penney

EFX

Equifax

DIS

Disney

BLFS

BioLife Solutions

$5.15

0.14 (2.79%)

HTZ

Hertz

NVDA

Nvidia

$205.32

-3.84 (-1.84%)

IMMU

Immunomedics

$10.44

0.31 (3.06%)

CAE

CAE

TTD

Trade Desk

$59.28

-2.37 (-3.84%)

RDFN

Redfin

$23.20

1.5 (6.91%)

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 16

    Nov

  • 14

    Dec

JCP J.C. Penney

10/30/17
10/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. 2. Merck (MRK) downgraded to Hold from Buy at SunTrust and to Equal Weight from Overweight at Morgan Stanley, as well as Barclays. 3. J.C. Penney (JCP) downgraded to Sell from Neutral at Citi, to Neutral from Buy at Northcoast, and to Neutral from Positive at Susquehanna. 4. Macy's (M) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying the retailer's sales and margins have been pressured for several years, and J.C. Penney's weak third quarter preannouncement on Friday serves as reminder of just how challenging the department store space is. 5. Under Armour (UAA, UA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes saying he expects management to lower fourth quarter guidance on its Q3 conference call due to the highly promotional environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/17
NRCS
10/30/17
DOWNGRADE
NRCS
Neutral
J.C. Penney downgraded to Neutral from Buy at Northcoast
10/30/17
SUSQ
10/30/17
DOWNGRADE
Target $3
SUSQ
Neutral
J.C. Penney downgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Bill Dreher downgraded J.C. Penney to Neutral from Positive following its Q3 results. The analyst cited its continued gross margin pressures and the fact that sales driving initiatives are taking longer than expected to materialize. Dreher lowered his price target to $3 from $6.50 on J.C. Penney shares.
10/30/17
SBSH
10/30/17
DOWNGRADE
Target $16
SBSH
Sell
Macy's downgraded to Sell from Neutral at Citi
Citi analyst Paul Lejuez downgraded Macy's (M) to Sell and cut his price target for the shares to $16 from $21. The retailer's sales and margins have been pressured for several years, and J.C. Penney's (JCP) weak Q3 preannouncement on Friday serves as reminder of just how challenging the department store space is, Lejuez tells investors in a research note. He believes risks are mounting at Macy's ahead of what is likely to be another promotional holiday season. Macy's has not found the right tools to offset negative store traffic and margin pressures, the analyst contends. Lejuez this morning also downgraded Penny to Sell.
EFX Equifax

10/23/17
RBCM
10/23/17
DOWNGRADE
Target $113
RBCM
Sector Perform
Equifax downgraded to Sector Perform on post-breach uncertainty at RBC Capital
As previously noted, RBC Capital analyst Gary Bisbee downgraded Equifax to Sector Perform from Outperform and kept his $113 price target. Bisbee says the stock price had a "healthy" rally off the post-breach lows but will likely be rangebound for several quarters as the impact of the breach plays out. The analyst notes that significant uncertainty remains over the financial, operational, and regulatory impact from the security breach, capping upside valuation.
10/30/17
10/30/17
DOWNGRADE
Target $54

Equal Weight
TransUnion downgraded to Equal Weight after rally at Morgan Stanley
As previously reported, Morgan Stanley analyst Toni Kaplan downgraded TransUnion (TRU) to Equal Weight from Overweight, stating that the company's strong growth opportunities are now priced in following the stock's 74% year-to-date advance. While the company could gain share at the expense of Equifax (EFX), this is offset by the potential headwinds of regulatory and legislative changes and the slower extension of credit, Kaplan tells investors. She raised her price target on TransUnion shares to $54 from $51.
11/08/17
GSCO
11/08/17
INITIATION
Target $116
GSCO
Neutral
Equifax initiated with a Neutral at Goldman Sachs
Goldman analyst George Tong initiated Equifax with a Neutral and $116 price target saying he expects shares to be range bound until cyberattack related issues subside.
10/23/17
RBCM
10/23/17
DOWNGRADE
RBCM
Sector Perform
Equifax downgraded to Sector Perform from Outperform at RBC Capital
DIS Disney

11/10/17
EVER
11/10/17
NO CHANGE
Target $120
EVER
Outperform
Evercore ISI incrementally optimistic on Disney's FY18 outlook
Evercore ISI analyst Vijay Jayant came away from Disney's lackluster Q4 report incrementally optimistic on the company's FY18 outlook. He said the massive film slate for the coming year should translate into double-digit full year revenue and OIBDA gains, while underlying trends at the media networks division are improving. Jayant believes management is making the right strategic decisions and the fresh guidance could be a modest postive for sentiment. Jayant rares Disney and Outperform with a $120 price target.
11/10/17
BERN
11/10/17
NO CHANGE
Target $101
BERN
Market Perform
Disney deal for Fox wouldn't solve underlying problems, says Bernstein
Bernstein analyst Todd Juenger noted that Disney (DIS) has gone from a situation where reported EPS was going up but its stock price was going down to one where EPS is going down but the stock has been going up a bit driven by M&A speculation. However, he contends that the current round of renewed M&A speculation is happening because underlying fundamentals are "so bad" and even if a deal for Disney to buy Fox (FOXA) assets happens it wouldn't solve the underlying problems. He also thinks the chances of a Disney-Fox deal as currently described are "very low." Juenger maintains a Market Perform rating and $101 price target on Disney shares.
11/10/17
LOOP
11/10/17
NO CHANGE
Target $104
LOOP
Hold
Disney revenue miss due to shortfall at Media Networks, says Loop Capital
Loop Capital analyst David Miller says Disney's revenue miss was largely the result of a notable shortfall at Media Networks, where sales of $5.46B were down 3.4% on the year largely because of lower advertising sales at ABC. Media's EBIT result was constrained by higher NBA rights costs, says the analyst, adding that Disney CFO has also warned that ESPN ad sales are pacing down in Q1. Miller notes that Disney's Theme Parks division is performing well, with Q4 revenues rising 6.4% thanks to higher occupancy levels at both Orlando and Anaheim along with the effects of surge pricing. The analyst keeps his Hold rating and nudges the price target to $104 from $103 following Q4 results.
11/10/17
PIPR
11/10/17
NO CHANGE
Target $120
PIPR
Overweight
Disney price target lowered to $120 from $130 at Piper Jaffray
Piper Jaffray analyst Stan Meyers lowered his price target for Disney shares to $120 saying investments into BamTech, Hulu, lower ratings at ABC/ESPN and Hurricane Irma drove the miss in Q4. The analyst, however, remains "upbeat" on the shares citing a "strong" film slate, growth from recent and upcoming carriage renewals, and continued momentum at the Parks. Meyers keeps an Overweight rating on Disney.
BLFS BioLife Solutions
$5.15

0.14 (2.79%)

01/19/17
MAXM
01/19/17
INITIATION
Target $3
MAXM
Buy
BioLife Solutions initiated with a Buy at Maxim
Maxim analyst Gabrielle Zhou started BioLife Solutions (BLFS) with a Buy rating and $3 price target, saying that its biopreservation media products for cell therapy have advantages over competing media products. Kite Pharma's (KITE) KTE-C19 could be approved in 2017, which would be a milestone for the cell therapy space and a catalyst for BioLife, Zhou tells investors.
03/10/17
MAXM
03/10/17
NO CHANGE
Target $4
MAXM
Buy
BioLife Solutions price target raised to $4 from $3 at Maxim
Maxim analyst Gabrielle Zhou increased her out year estimates for BioLife Solutions' media products citing demand growth as the cell therapy space grows and raised her price target to $4 from $3. The analyst, who thinks BioLife's media products and shipping platform offer advantages that the cell therapy space will continue to adopt, keeps a Buy rating on the shares.
07/05/17
JANY
07/05/17
UPGRADE
JANY
Buy
BioLife Solutions upgraded to Buy from Neutral at Janney Capital
07/05/17
07/05/17
UPGRADE
Target $5

Buy
BioLife Solutions upgraded to Buy at Janney Capital
As previously reported, Janney Capital upgraded BioLife Solutions to Buy from Neutral with a $5 price target saying Novartis' July 12 FDA hearing is the last step before CTL019 approval and signals the beginning of the regenerative medicine era. Further, with a recurring revenue stream and over 20 products in Phase III trials, the analyst believes growth can accelerate.
HTZ Hertz

10/12/17
MKMP
10/12/17
NO CHANGE
Target $49
MKMP
Buy
Car rental group earnings to inflect on improved fundamentals, says MKM Partners
MKM Partners analyst Christopher Agnew raised his price target on Avis Budget Group (CAR) to $49 from $39 and Hertz Global (HTZ) to $36 from $22, maintaining a Buy rating on both stocks. Agnew says the earnings momentum for the group is at an upward inflection point thanks to sustained improvement in core fundamentals, as net pricing is turning positive. Agnew also notes other catalysts for these stocks, including overly high 40-50% short interest and cost reductions driven by "connected-cars" technology improvements.
10/02/17
SUSQ
10/02/17
NO CHANGE
SUSQ
NADA data show slight improvement in September used car prices, says Susquehanna
Susquehanna said that data from NADA showed that seasonally adjusted used car prices declined 4.1% year-over-year and increased 1.2% month-over-month in September. While the firm expects recent hurricanes to be a near-term benefit to used car prices, it thinks any near-term improvement will be short-lived. Hertz (HTZ) and Avis Budget (CAR) are near-session highs in afternoon trading.
10/06/17
DBAB
10/06/17
NO CHANGE
Target $49
DBAB
Buy
Deutsche Bank raises price targets in Rental Car space
Deutsche Bank analyst Chris Woronka raised his price target for Buy-rated Avis Budget Group (CAR) to $49 from $44 and for Hold-rated Hertz Global Holdings (HTZ) to $18 from $14. Both companies' third quarters were tracking favorably on both demand and pricing in the U.S. even before the hurricanes, Woronka tells investors in a research note. He believes the storms are likely to have a larger impact on demand in Q4 but a larger positive impact on residual values in Q3. The analyst raised his estimates "above consensus across the board" for both companies.
11/10/17
MSCO
11/10/17
NO CHANGE
Target $14
MSCO
Underweight
Hertz post-earnings 'squeeze' should be faded, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said Hertz has been "opportunistic" in extending debt maturities, which he sees allowing it to delay its credit problem. However, he does not expect the fundamentals of the car rental business to improve and he thinks after a pause it will see further and potential steeper declines. Jonas, who thinks Hertz may still need to take "far more radical and preemptive action," keeps an Underweight rating on the shares and recommends investors "fade the squeeze" in the stock following the company's earnings report.
NVDA Nvidia
$205.32

-3.84 (-1.84%)

11/10/17
ADAM
11/10/17
NO CHANGE
Target $225
ADAM
Buy
Nvidia price target raised to $225 after earnings at Canaccord
Canaccord analyst Matthew Ramsay noted Nvidia reported another quarter that not only beat his expectations but consensus as well. Management believes the company remains well positioned to serve the cryptocurrency market long-term, while continuing to execute strongly in several secular growth markets. Ramsay said with the strong growth drivers intact, he reiterates his Buy rating and raised his price target to $225 from $190 on Nvidia shares.
11/10/17
RBCM
11/10/17
NO CHANGE
Target $240
RBCM
Outperform
Nvidia price target raised to $240 from $230 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Nvidia to $240 and kept his Outperform rating after Q3 results. Steves says the company was able to meet and exceed estimates for Data Center and Gaming, adding that the 3% after-market stock price gains are likely to hold. The analyst also notes that the impact from crypto currencies should fade now that the profitability of a mining rig has hit levels seen in early 2017 and the topic will fade from investor focus in the near-term.
11/10/17
RAJA
11/10/17
NO CHANGE
Target $250
RAJA
Outperform
Nvidia price target raised to $250 from $180 at Raymond James
Raymond James analsyt Chris Caso raised Nvidia's price target to $250 saying the company continues to surpise and remains on a mid-30's year-over-year growth rate and finds it a difficult stock not to own. Caso has an Outperform ratingon shares..
11/10/17
MSCO
11/10/17
NO CHANGE
Target $222
MSCO
Equal Weight
Morgan Stanley ups Nvidia target to $222, keeps Equal Weight based on valuation
Morgan Stanley analyst Joseph Moore noted that Nvidia reported results that topped even his recently raised expectations, driven by significant upside in its core gaming segment. He raised his EPS estimates and increased his price target on Nvidia shares to $222 from $210, but maintains an Equal Weight rating citing the stock's valuation.
IMMU Immunomedics
$10.44

0.31 (3.06%)

07/24/17
COWN
07/24/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics shares remain significantly undervalued, says Cowen
Cowen analyst Phil Nadeau believes Immunomedics shares remain significantly undervalued, citing the potential for its IMMU-123 filing in mTNBC. Nadeau, who said with steady progress the BLA is on track for a filing in Q4 or the next quarter, reiterated his Outperform rating and $15 price target on Immunomedics shares.
08/17/17
JEFF
08/17/17
NO CHANGE
Target $11
JEFF
Buy
Jefferies likes setup for Immunomedics despite 113% rally year-to-date
Jefferies analyst Matthew Andrews says that even though shares of Immunomedics are up 113% year-to-date, he still likes the setup into the end of 2017 and into Q1 of 2018. The company remains his top small-cap pick with a Buy rating and $11 price target. The analyst sees a potential new CEO and final triple-negative breast cancer data in December as potential catalysts.
08/17/17
COWN
08/17/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics significantly undervalued, says Cowen
Cowen analyst Philip Nadeau said the Immunomedics submission of IMMU-132 BLA is on track and he expects the company to release updated results during the second half of the year for submission in Q4 or Q1. The analyst continues to think the shares are significantly undervalued given the drug's potential. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
09/19/17
JEFF
09/19/17
NO CHANGE
Target $14
JEFF
Buy
Immunomedics price target raised to $14 from $11 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $14 saying the updated IMMU-132 data in bladder cancer "continue to impress." The analyst sees continued upside through year-end. He continues to view Immunomedics as a top small-cap pick with a Buy rating.
CAE CAE

06/01/17
TDSI
06/01/17
DOWNGRADE
TDSI
Hold
CAE downgraded to Hold from Buy at TD Securities
TD Securities analyst Tim James downgrade CAE to Hold from Buy citing valuation.
06/01/17
06/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Archer Daniels (ADM) downgraded to Hold from Buy at Argus with analyst David Coleman saying he expects the company's profits to be lowered by grain oversupplies for the rest of this year. He thinks that the company's dividend increases may be "limited" going forward. 2. CAE (CAE) downgraded to Hold from Buy at TD Securities with analyst Tim James citing valuation. 3. Sinopec Shanghai (SHI) downgraded to Sell from Neutral at Citi. 4. Rayonier Advanced Materials (RYAM) downgraded to Hold from Buy at Vertical Research with analyst Chip Dillon citing valuation. 5. Fox Factory (FOXF) downgraded to Neutral from Buy at CL King with analyst Scott Stember citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/17
BMOC
08/30/17
UPGRADE
BMOC
Outperform
CAE upgraded to Outperform from Market Perform at BMO Capital
08/30/17
BMOC
08/30/17
UPGRADE
BMOC
Outperform
CAE upgraded on valuation at BMO Capital
As noted earlier, BMO Capital upgraded CAE to Outperform from Market Perform. Analyst Fadi Chamoun upgraded the stock based on valuation, saying that the company's fundamentals remain strong and that there is "no fundamental reason" for the stock's recent retreat. The analyst is upbeat on the company's purchase of a 50% share of an AirAsia joint venture and its recently signed joint venture with Singapore Airlines. Target $23.
TTD Trade Desk
$59.28

-2.37 (-3.84%)

11/10/17
MACQ
11/10/17
NO CHANGE
Target $68
MACQ
Trade Desk recommended following the Q3 beat at Macquarie
Macquarie analyst Tim Nolan said to Buy Trade Desk on "another Q3 beat" and raise. The analyst said management's bullish tone was unchanged and still sees excellent store growth. He said any near-term weakness in shares is a buying opportunity for this fast growing ad-tech business capitalizing on automation trends.
11/10/17
SUSQ
11/10/17
NO CHANGE
Target $70
SUSQ
Positive
Trade Desk dip should be bought, says Susquehanna
Susquehanna analyst Shyam Patil said Trade Desk continues to gain market share across the programmatic spectrum and believes the story is still in the early innings. He sees emerging opportunities and views the company as the clear leader with superior technology. He said the business momentum remains strong and any dip should be bought. Patil reiterated his Positive rating and raised his price target to $70 from $66 on Trade Desk shares.
10/12/17
MACQ
10/12/17
INITIATION
Target $78
MACQ
Outperform
Trade Desk initiated with an Outperform at Macquarie
Macquarie analyst Tim Nollen initiated Trade Desk with an Outperform and $78 price target saying it has one of the premier independent programmatic demand-side platforms in the ad industry. The analyst believes Trade Desk is a tech company operating a SaaS model with a 95% customer retention rate and 30%+ adjusted EBITDA margins that are expected to expand to 40% long-term.
10/06/17
NEED
10/06/17
NO CHANGE
Target $66
NEED
Buy
Trade Desk price target raised to $66 from $62 at Needham
Needham analyst Kerry Rice raised his price target on Trade Desk to $66 and maintained his Buy rating following the company's analyst day on Wednesday. Rice notes "the future is bright" for the company on expectations of proliferating ad-funded models and increasing trends of on-demand TV options by consumers. The analyst is also constructive on the company's potential for international expansion, with only about 12% of overall revenue generated overseas.
RDFN Redfin
$23.20

1.5 (6.91%)

08/22/17
BOFA
08/22/17
INITIATION
Target $28
BOFA
Neutral
Redfin initiated with a Neutral at BofA/Merrill
BofA/Merrill initiated Redfin with a Neutral and a $28 price target.
10/19/17
WBLR
10/19/17
INITIATION
WBLR
Outperform
Redfin initiated with an Outperform at William Blair
William Blair analyst Brandon Dobell started Redfin with an Outperform rating saying the company offers a "compelling" value proposition for consumers. The analyst expects residential housing activity to remain "healthy."
09/28/17
PIPR
09/28/17
INITIATION
Target $26
PIPR
Neutral
Redfin initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Jason Deleeuw started Redfin with a Neutral rating and $26 price target. The analyst sees headwinds to the company's relative valuation amid its ongoing investments in lead generation and agent employees.
08/22/17
08/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with a Sector Perform at RBC Capital, Hold rating at Stifel, an Outperform at Oppenheimer and Neutral at Goldman Sachs. 2. Energen (EGN) initiated with an Outperform at Imperial Capital. 3. Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital. 4. Revance (RVNC) initiated with an Outperform at JMP Securities. 5. Pacira (PCRX) initiated with a Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.